



INNOVATION | QUALITY | CARE

Date: July 3, 2026

To,
The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street – Fort
Mumbai 400 001
Scrip Code: 544578

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th floor, Plot no. C/1, G Block
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051
NSE Symbol: RUBICON

Dear Sir / Madam,

Subject: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – US FDA inspection of the Company’s manufacturing facility in Pithampur, Madhya Pradesh

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food and Drug Administration (US FDA) conducted an unannounced inspection of the company’s manufacturing facility located at Plot No. A-17, Special Economic Zone, Phase- II, Industrial Area, Pithampur, District Dhar, PIN – 454 775, Madhya Pradesh from Monday, 29 June 2026 to Friday, 3 July 2026.

This was the first US FDA inspection of this facility since its acquisition by the company last year. In the 12 months since the acquisition, we completed the integration of the facility, implemented our quality management systems and completed regulatory filings that initiated the inspection requirement.

Upon conclusion of the inspection, a Form 483 containing 2 observations was issued to the company. The observations are procedural in nature and do not relate to data integrity. The company is confident of working closely with the regulator to successfully conclude the evaluation in a timely manner. A successful inspection outcome in little over a year of acquiring the facility, shall reflect our deeply rooted quality & compliance culture and shall reinforce our strong regulatory track record.

As guided in our Q4 FY2026 investor update, the company remains confident of ramping up commercial operations at this facility from Q1 of calendar year 2027.

We will keep the stock exchanges duly informed of any further updates on this subject.

Kindly take the above intimation on record.

Yours faithfully,

For Rubicon Research Limited
(Formerly known as Rubicon Research Private Limited)

Deepashree Tanksale
Company Secretary
M. No. A28132

Rubicon Research Limited (formerly known as Rubicon Research Private Limited) | CIN: L73100MH1999PLC119744

Registered Office: Plot No. B-75, MedOne House, Road No. 33, Wagle Estate, Thane West, PIN – 400 604, Maharashtra, India

+91-22-61414000 / 50414000 | reachus@rubicon.co.in | www.rubicon.co.in